(Adds details on study and next steps in paragraphs 2-4)
Jan 6 (Reuters) - Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Shares of the drug developer were down 6.6% in extended trade following the announcement.
The study's main goal was to demonstrate a change in disease severity over time and increase survival, comparing DNL343 to a placebo, as measured by a specific scale.
"We remain deeply committed to fully understanding the effects of DNL343 in ALS and will further evaluate the data before determining next steps", said Merit Cudkowicz, the study's principal investigator.
A more comprehensive analysis of the study results will become available later in 2025, according to Carole Ho, the company's medical chief.
(Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。